Clinical Study

2125-Mel-301- A Randomized Phase 3 Comparison Of Imo-2125 With Ipilimumab Versus Ipilimumab Alone In Subjects With Anti-Pd-1 Refractory Melanoma

Posted Date: May 15, 2019

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to compare the efficacy (measured by OS and ORR) of intratumoral IMO-2125 in combination with ipilimumab versus ipilimumab alone.


To Be Eligible: Confirmed Diagnosis Of Metastatic Melanoma, >18 Years Of Age, Nonpregnant/Nonbreastfeeding, No Active Autoimmune Disease Or Another Malignancy Within 3 Yuers.


2125-Mel-301, Melanoma, Phase Iii, Skin Cancer

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.